Today the Supreme Court announced it would not hear the Sherley v Sebelius case, ending the court battle that has left embryonic stem cell research (ESCR) in what I’ve called a “big chill”. This is great news. It is all over the mainstream media. Even the rampant anti-science, pro-lifers have declared defeat. I’m not going …
A great day for stem cell research: more on SCOTUS & details on BioTime news Read More »
Today the Supreme Court agreed to review three cases, none of which were Sherley v Sebelius. What a great day! For those curious, Certiorari Granted (subheading on Supreme Court announcement) means the Court has granted review of these cases. This is wonderful news for patients, the stem cell field, and probably biotech Advanced Cell Technology …
Great news as Sherley v Sebelius officially over: Supreme Court Takes a pass! Read More »
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their …
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »
In previous years I’ve done yearly predictions for the coming year’s events in the stem cell world (see predictions for 2011 and 2012 predictions). I did pretty well in my predicting stem cell events for this year (see analysis here) scoring a respectable 70%. Isn’t that a C-?,you might ask. No, when it comes to …
Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials …
Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until …
Why I finally bought stock in Advanced Cell Technology Read More »
